Literature DB >> 30692217

The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.

Laura Icardi1, Giovanni Gambi2, Elisabetta Di Simone2, Veronica Basso2, Luisa Ricci2, Rui Wang3, Akanksha Verma4,5,6, Olivier Elemento4,5,6, Maurilio Ponzoni7, Giorgio Inghirami3,8,9, Anna Mondino1.   

Abstract

Epigenetic silencing of promoter and enhancer regions is a common phenomenon in malignant cells. The transcription factor STAT3 is aberrantly activated in several tumors, where its constitutive acetylation accounts for the transcriptional repression of a number of tumor suppressor genes (TSG) via molecular mechanisms that remain to be understood. Using nucleophosmin-anaplastic lymphoma kinase-positive (NPM-ALK+) anaplastic large-cell lymphoma (ALCL) as model system, we found in cells and patient-derived tumor xenografts that STAT3 is constitutively acetylated as a result of ALK activity. STAT3 acetylation relied on intact ALK-induced PI3K- and mTORC1-dependent signaling and was sensitive to resveratrol. Resveratrol lowered STAT3 acetylation, rescued TSG expression, and induced ALCL apoptotic cell death. STAT3 constitutively bound the Sin3A transcriptional repressor complex, and both STAT3 and Sin3A bound the promoter region of silenced TSG via a resveratrol-sensitive mechanism. Silencing SIN3A caused reexpression of TSG, induced ALCL apoptotic cell death in vitro, and hindered ALCL tumorigenic potential in vivo. A constitutive STAT3-Sin3A interaction was also found in breast adenocarcinoma cells and proved critical for TSG silencing and cell survival. Collectively, these results suggest that oncogene-driven STAT3 acetylation and its constitutive association with Sin3A represent novel and concomitant events contributing to STAT3 oncogenic potential. SIGNIFICANCE: This study delineates the transcriptional regulatory complex Sin3A as a mediator of STAT3 transcriptional repressor activity and identifies the STAT3/Sin3A axis as a druggable target to antagonize STAT3-addicted tumors. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/12/3076/F1.large.jpg.See related commentary by Monteleone and Poli, p. 3031. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30692217     DOI: 10.1158/0008-5472.CAN-18-0359

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Identification of key regulators associated with colon cancer prognosis and pathogenesis.

Authors:  Narges Toolabi; Fattane Sam Daliri; Amir Mokhlesi; Mahmood Talkhabi
Journal:  J Cell Commun Signal       Date:  2021-03-26       Impact factor: 5.782

Review 2.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

3.  Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo.

Authors:  Jian Chen; Xiaofei Huang; Cheng Tao; Li Wang; Zide Chen; Xinping Li; Qiang Zeng; Min Ma; Ren Zhang; Zhengzhi Wu
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-30       Impact factor: 3.333

Review 4.  Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.

Authors:  Ping Zhang; Mingzhi Zhang
Journal:  Clin Epigenetics       Date:  2020-11-07       Impact factor: 6.551

Review 5.  Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.

Authors:  Yuan Wang; Jing He; Manyu Xu; Qingfeng Xue; Cindy Zhu; Juan Liu; Yaping Zhang; Wenyu Shi
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

6.  Multi-Omics Analyses Revealed GOLT1B as a Potential Prognostic Gene in Breast Cancer Probably Regulating the Immune Microenvironment.

Authors:  Junping Liu; Wei Zhang; Wanxia Cai; Yumei Chen; Xiaozhong Cai; Donge Tang; Min Tang; Yong Dai
Journal:  Front Oncol       Date:  2022-01-19       Impact factor: 6.244

7.  Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.

Authors:  Suhu Liu; Helen I Gandler; Isidora Tošić; Darwin Q Ye; Zachary T Giaccone; David A Frank
Journal:  Mol Cancer Res       Date:  2021-04-30       Impact factor: 5.852

Review 8.  Targeting STAT3 in Cancer Immunotherapy.

Authors:  Sailan Zou; Qiyu Tong; Bowen Liu; Wei Huang; Yan Tian; Xianghui Fu
Journal:  Mol Cancer       Date:  2020-09-24       Impact factor: 27.401

9.  Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway.

Authors:  Lehe Yang; Tianru Zhu; Hua Ye; Yili Shen; Zhiping Li; Luye Chen; Canwei Wang; Xia Chen; Haiyang Zhao; Youqun Xiang; Zhongxiang Xiao; Chengguang Zhao; Jifa Li; Wanle Hu
Journal:  J Cell Mol Med       Date:  2020-12-01       Impact factor: 5.295

10.  Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women.

Authors:  Babatunde Adedokun; Zhaohui Du; Guimin Gao; Thomas U Ahearn; Kathryn L Lunetta; Gary Zirpoli; Jonine Figueroa; Esther M John; Leslie Bernstein; Wei Zheng; Jennifer J Hu; Regina G Ziegler; Sarah Nyante; Elisa V Bandera; Sue A Ingles; Michael F Press; Sandra L Deming-Halverson; Jorge L Rodriguez-Gil; Song Yao; Temidayo O Ogundiran; Oladosu Ojengbede; William Blot; Melissa A Troester; Katherine L Nathanson; Anselm Hennis; Barbara Nemesure; Stefan Ambs; Peter N Fiorica; Lara E Sucheston-Campbell; Jeannette T Bensen; Lawrence H Kushi; Gabriela Torres-Mejia; Donglei Hu; Laura Fejerman; Manjeet K Bolla; Joe Dennis; Alison M Dunning; Douglas F Easton; Kyriaki Michailidou; Paul D P Pharoah; Qin Wang; Dale P Sandler; Jack A Taylor; Katie M O'Brien; Cari M Kitahara; Adeyinka G Falusi; Chinedum Babalola; Joel Yarney; Baffour Awuah; Beatrice Addai-Wiafe; Stephen J Chanock; Andrew F Olshan; Christine B Ambrosone; David V Conti; Elad Ziv; Olufunmilayo I Olopade; Montserrat Garcia-Closas; Julie R Palmer; Christopher A Haiman; Dezheng Huo
Journal:  Nat Commun       Date:  2021-07-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.